Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
- 18 years ago
QualityStocks
Sinovac Biotech, Ltd. (AMEX: SVA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…
-
QualityStocksNewsBreaks – Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) Expands Coverage of Precision Cardiovascular Tests Through Atlas Healthcare Physicians
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare…
-
QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded…